Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 22, 2022

Primary Completion Date

June 29, 2023

Study Completion Date

June 29, 2023

Conditions
Asthma
Interventions
DRUG

Dupilumab

"Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.~Additionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints."

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

University of Michigan

OTHER